ADC Therapeutics SA (ADCT): Total Liabilities
$508.98M
As of 2025-12-31
$507.58M
As of 2026-06-30
+7.4%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $508.98M | -3.0% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $524.62M | +4.3% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $503.03M | +22.3% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $411.41M | n/a | 2024-03-13, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $508.98M | -3.0% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $57.16M | -44.6% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $65.96M | +27.6% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $149.39M | +4.9% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $213.39M | +126.2% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $143.46M | +2.0% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $52.56M | -56.6% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $2.08B | +35.6% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $390.05M | +28.1% |
Compare ADCT, ARCT, ETON, NRIX side by side · Screen every company in Pharmaceutical Preparations ↗